Inverse association of N-terminal pro-B-type natriuretic peptide with metabolic syndrome in patients with congestive heart failure

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Chang, Huai Ren ^a,b   Hsieh, Jen Che ^a   Hsu, Bang Gee ^a,b   Wang, Ling Yi ^c   Chen, Michael Yu Chih ^a,b   Wang, Ji Hung ^a,b  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; FASTING; FEMALE; HEART FAILURE; HUMANS; INSULIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS;

EID: 84893391271     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079096     Document Type: Article

References (35)

1. Raizada V, Thakore K, Luo W, McGuire PG (2001) Cardiac chamber-specific alterations of ANP and BNP expression with advancing age and with systemic hypertension. Mol Cell Biochem 216: 137-140.
2. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, et al. (2004) Impact of obesity on plasma natriuretic peptide levels. Circulation 109: 594-600.
3. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, et al. (2007) Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 115: 1345-1353.
4. Hobbs FD, Davis RC, Roalfe AK, Hare R, Davies MK, et al. (2002) Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ 324: 1498-1502.
5. Karabulut A, Kaplan A, Aslan C, Iltumur K, Toprak G, et al. (2005) The association between NT-proBNP levels, functional capacity and stage in patients with heart failure. Acta Cardiol 60: 631-638.
6. Dessi-Fulgheri P, Sarzani R, Tamburrini P, Moraca A, Espinosa E, et al. (1997) Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression osain adipose tissue of normotensive and hypertensive obese patients. J Hypertens 15: 1695-1699.
7. Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365: 1415-1428.
8. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-2752.
9. Miura Y, Fukumoto Y, Shiba N, Miura T, Shimada K, et al. (2010) Prevalence and clinical implication of metabolic syndrome in chronic heart failure. Circ J 74: 2612-2621.
10. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, et al. (2005) N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 46: 660-666.
11. Bao Y, Shang X, Zhou L, Hu R, Li Y, et al. (2011) Relationship between Nterminal pro-B-type natriuretic peptide levels and metabolic syndrome. Arch Med Sci 7: 247-256.
12. Cheng S, Fox CS, Larson MG, Massaro JM, McCabe EL, et al. (2011) Relation of visceral adiposity to circulating natriuretic peptides in ambulatory individuals. Am J Cardiol 108: 979-984.
13. Taylor JA, Christenson RH, Rao K, Jorge M, Gottlieb SS (2006) B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am Heart J 152: 1071-1076.
14. St Peter JV, Hartley GG, Murakami MM, Apple FS (2006) B-type natriuretic peptide (BNP) and N-terminal pro-BNP in obese patients without heart failure: relationship to body mass index and gastric bypass surgery. Clin Chem 52: 680-685.
15. Bertoni AG, Wagenknecht LE, Kitzman DW, Marcovina SM, Rushing JT, et al. (2012) Impact of the look AHEAD intervention on Nt-pro brain natriuretic peptide in overweight and obese adults with diabetes. Obesity 20: 1511-1518.
16. Lazo M, Young JH, Brancati FL, Coresh J, Whelton S, et al. (2013) N-terminal pro-brain aatriuretic peptide and risk of diabetes. Diabetes Jun 3 Epub aheadof print.
17. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, et al. (2009) 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adult. Circulation 119: e391-e479.
18. Allanore Y, Borderie D, Meune C, Cabanes L, Weber S, et al.(2003) N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum 48: 3503-3508.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
20. Legro RS, Finegood D, Dunaif A (1998) A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 83: 2694-2698.
21. Alberti KG, Zimmet PZ, Shaw J (2006) Metabolic syndrome - a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23: 469-480.
22. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553.
23. Remme WJ, Swedberg K (2001) Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 22: 1527-1560.
24. Sakhuja R, Januzzi J (2004) Nt-proBNP: a new test for diagnosis, prognosis and management of congestive heart failure. US Cardiology 1: 1-5.
25. Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, et al. (2003) Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 338: 107-115.
26. Bionda C, Bergerot C, Ardail D, Rodriguez-Lafrasse C, Rousson R (2006) Plasma BNP and NT-proBNP assays by automated immunoanalyzers: analytical and clinical study. Ann Clin Lab Sci 36: 299-306.
27. Koizumi M, Watanable H, Kaneko Y, Iino K, Ishida M, et al. (2012) Impact of obesity on plasma B-type natriuretic peptide levels in Japanese community-based subjects. Heart Vessels 27: 287-294.
28. Beleigoli AM, Diniz MF, Ribeiro AL (2009) Natriuretic peptides: linking heart and adipose tissue in obesity and related conditions - a systemic review. Obesity Reviews 10: 617-626.
29. Costello-Boerrigter LC, Burnrtt JC Jr (2009) A new role for the natriuretic peptides. J Am Coll Cardiol 53: 2078-2079.
30. Boerrigter G, Burnett JC Jr (2004) Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Invest Drugs 13: 643-652.
31. Garbers DL, Chrisman TD, Wiegn P, Katafuchi T, Albanesi JP, et al. (2006) Membrane guanylyl cyclase receptors: an update. Trends Endocrinol Metab 17: 251-258.
32. Sengenes C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J (2000) Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J 14: 1345-1351.
33. Addisu A, Gower WR Jr., Landon CS, Dietz JR (2008) B-type natriuretic peptide decreases gastric emptying and absorption. Exp Biol Med (Maywood) 233: 475-482.
34. Sengenes C, Bouloumie A, Hauner H, Berlan M, Busse R, et al. (2003) Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J Biol Chem 278: 48617-48626.
35. Sengenes C, Zakaroff-Girard A, Moulin A, Berlan M, Bouloumie A, et al. (2002) Natriuretic peptidedependent lipolysis in fat cells is a primate specificity. Am J Physiol Regul Integr Comp Physiol 283: R257-R265.